Picture of Prestige Biopharma logo

950210 — Prestige Biopharma Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapSucker Stock

Momentum

Relative Strength (%)
1m-0.36%
3m-22.44%
6m-30.76%
1yr-51.23%
Volume Change (%)
10d/3m-50.76%
Price vs... (%)
52w High-71.6%
50d MA-16.81%
200d MA-39.76%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)3.35
PEG Ratio (f)0.04
EPS Growth (f)1,948.53%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value1.29
Price to Tang. Book1.45
Price to Free Cashflown/a
Price to Salesn/a
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-5.99%
Return on Equity-19.7%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Prestige Biopharma EPS forecast chart

Profile Summary

Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. The Company's biosimilar portfolio includes Herceptin Biosimilar (HD201), Avastin Biosimilar (HD204), and Humira Biosimilar (PBP1502). Its antibody therapeutics portfolio includes PBP1510 Anti-PAUF antibody for pancreatic cancer and PBP1710 Anti-CTHRC1 antibody for solid tumors. Its products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Its IDC001 is designed to treat cancers that express relatively high levels of PAUF and CTHRC1. The Company's manufacturing facilities for global commercial supply are located in Osong, South Korea.

Directors

    Last Annual
    June 30th, 2021
    Last Interim
    March 31st, 2022
    Incorporated
    July 13th, 2015
    Public Since
    February 5th, 2021
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    kr flag iconKorea Exchange - KSE
    Shares in Issue
    12,019,231

    950210 Share Price Performance

    Upcoming Events for 950210

    Similar to 950210

    Picture of Aprogen Pharmaceuticals logo

    Aprogen Pharmaceuticals

    kr flag iconKorea Exchange - KSE

    Picture of Boryung logo

    Boryung

    kr flag iconKorea Exchange - KSE

    Picture of Bukwang Pharm Co logo

    Bukwang Pharm Co

    kr flag iconKorea Exchange - KSE

    Picture of Chongkundang Holdings logo

    Chongkundang Holdings

    kr flag iconKorea Exchange - KSE

    Picture of Chong Kun Dang Pharmaceutical logo

    Chong Kun Dang Pharmaceutical

    kr flag iconKorea Exchange - KSE

    FAQ

    Or unlock with your email

    Or unlock with your email